Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Seer (Nasdaq: SEER), a pioneer in proteomics platform technology, has announced its participation in the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco. The company's management team will deliver a presentation and engage in a Q&A session on Wednesday, January 15th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend the live presentation, an archived replay will be made available on the company's website after the conference concludes.
Seer (Nasdaq: SEER), pioniere nella tecnologia delle piattaforme proteomiche, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale sulla Salute di J.P. Morgan a San Francisco. Il team di gestione dell'azienda terrà una presentazione e parteciperà a una sessione di domande e risposte mercoledì 15 gennaio alle 15:00 ora del Pacifico / 18:00 ora dell'Est.
Investitori e parti interessate possono accedere a una diretta streaming della sessione tramite la sezione Investitori del sito web di Seer all'indirizzo investor.seer.bio. Per coloro che non possono partecipare alla presentazione dal vivo, sarà disponibile una registrazione archiviata sul sito dell'azienda dopo la conclusione della conferenza.
Seer (Nasdaq: SEER), pionera en la tecnología de plataformas de proteómica, ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan en San Francisco. El equipo de gestión de la empresa ofrecerá una presentación y participará en una sesión de preguntas y respuestas el miércoles 15 de enero a las 3:00 p.m. hora del Pacífico / 6:00 p.m. hora del Este.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la sesión a través de la sección de Inversores del sitio web de Seer en investor.seer.bio. Para quienes no puedan asistir a la presentación en vivo, se pondrá a disposición una repetición archivada en el sitio web de la empresa después de que concluya la conferencia.
Seer (Nasdaq: SEER)는 단백질체 분석 플랫폼 기술의 선구자로서 샌프란시스코에서 열리는 J.P. Morgan 제43회 연례 건강회의에 참여한다고 발표했습니다. 회사의 경영진은 1월 15일 수요일 오후 3시(태평양 표준시) / 오후 6시(동부 표준시)에 발표를 진행하고 Q&A 세션에 참여할 예정입니다.
투자자와 이해 관계자는 Seer 웹사이트의 투자자 섹션을 통해 세션의 라이브 웹캐스트에 접근할 수 있습니다. 라이브 발표에 참석할 수 없는 분들은 회의가 종료된 후 회사 웹사이트에서 아카이브된 재생을 이용할 수 있습니다.
Seer (Nasdaq: SEER), pionnier de la technologie des plateformes de protéomique, a annoncé sa participation à la 43ème Conférence Annuelle sur la Santé de J.P. Morgan à San Francisco. L'équipe de direction de l'entreprise fera une présentation et participera à une séance de questions-réponses le mercredi 15 janvier à 15h00 heure du Pacifique / 18h00 heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la session via la section Investisseurs du site web de Seer à l'adresse investor.seer.bio. Pour ceux qui ne peuvent pas assister à la présentation en direct, une rediffusion archivées sera disponible sur le site de l'entreprise après la fin de la conférence.
Seer (Nasdaq: SEER), ein Pionier in der Proteomik-Plattformtechnologie, hat seine Teilnahme an der 43. J.P. Morgan Annual Healthcare Conference in San Francisco bekannt gegeben. Das Management-Team des Unternehmens wird am Mittwoch, den 15. Januar um 15:00 Uhr pazifischer Zeit / 18:00 Uhr östlicher Zeit eine Präsentation halten und an einer Fragen-und-Antworten-Runde teilnehmen.
Investoren und Interessierte können über den Investorenbereich der Seer-Website unter investor.seer.bio auf ein Live-Webcast der Sitzung zugreifen. Für diejenigen, die nicht an der Live-Präsentation teilnehmen können, wird im Anschluss an die Konferenz eine aufgezeichnete Wiederholung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA.
Seer’s management is scheduled to present and participate in a Q&A session on Wednesday, January 15th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
When is Seer (SEER) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Seer's presentation at the J.P. Morgan Healthcare Conference?
What type of session will Seer (SEER) conduct at the J.P. Morgan Healthcare Conference?
Where is the J.P. Morgan Healthcare Conference featuring Seer being held?
